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The Japanese Association for Thoracic Surgery has con-
ducted annual surveys of thoracic surgery throughout Japan
since 1986 to establish the statistics for the number of
procedures by operative category. The results from our
annual survey of thoracic surgery performed in 2016 are
summarized.
As has been done so far, thoracic surgery was classified
into three categories (cardiovascular, general thoracic, and
esophageal surgery), and the patient data were examined
and analyzed for each group. Access to the computerized
data is offered to all members of this Association. We
honor and value all members’ continued professional
support and contributions (Tables 1, 2).
The incidence of hospital mortality was added to the
survey to clarify the situation nationwide, which has con-
tributed to Japanese surgeons understanding the present
status of thoracic surgery in Japan and to make progress to
improve operative results by comparing their work with
that of others. The Association was able to gain a better
understanding of present problems, as well as future pro-
spects, which has been reflected in its activities, including
education of its members.
Thirty-day mortality (so called ‘‘operative mortality’’) is
defined as death within 30 days of operation regardless of
the patient’s geographic location and even after the patient
has been discharged from the hospital. Hospital mortality is
defined as death within any time interval after an operation
if the patient has not been discharged from the hospital.
Hospital-to-hospital transfer in the categories of eso-
phageal surgery is not considered discharge: transfer to a
nursing home or a rehabilitation unit is considered hospital
discharge unless the patient subsequently dies of compli-
cations of the operation. On the other hand, hospital-to-
hospital transfer 30 days after operation in the categories of
cardiovascular surgery and general thoracic surgery is
considered discharge because data of the national clinical
database (NCD) 2016 were used in this category, and
hospital-to-hospital transfer 30 days after operation is
considered discharge in the NCD.
Abstract of the survey
All data regarding cardiovascular surgery and thoracic
surgery were obtained from the NCD, whereas data
regarding esophageal surgery were collected from a survey
questionnaire by The Japanese Association for Thoracic
Surgery forms because NCD of esophageal surgery does
not include non-surgical cases (i.e. patients with adjuvant
chemotherapy or radiation alone).
In association with the change in data collection of
cardiovascular surgery from self-reports using question-
naire sheets in each participating institution until the report
in 2014 to automatic package download from the JCVSD
(Japanese Cardiovascular Surgery Database, a cardiovas-
cular part of the NCD), the response rate is not available
and is not indicated in the category of cardiovascular sur-
gery (Table 1). Further, the number of institutions classi-
fied by operation number is also not calculated in the
category of cardiovascular surgery (Table 2).
Annual report by The Japanese Association for Thoracic
Surgery: Committee for Scientific Affair.
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2016 Final report
(A) Cardiovascular surgery
First, we are very pleased with our colleagues’ (members’)
cooperation with our survey of cardiovascular surgery, which
definitely enhances the quality of this annual report. We are
truly grateful again for the enormous effort put into com-
pleting the JCVSD/NCD at each participating institution.
Figure 1 shows the development of cardiovascular surgery
in Japan over the last 30 years. Aneurysm surgery includes
only operations for thoracic and thoracoabdominal aortic
aneurysms. Extra-anatomic bypass surgery for thoracic
aneurysms and pacemaker implantationwere totally excluded
from the survey since 2015. The number of assist device
implantation operations is not included in the total number of
surgical operations, while it remained in the survey.
A totalof67,867cardiovascularoperations, including51heart
transplantations, were performed at 580 institutions in 2016,
which increased by 6.8% from the survey in 2015 (n = 63,520).
Considering the trend in 2016, the data of which were collected
and aggregated in the samemethod as in 2015, the actual number
of cardiovascular operations is still continuously increasing,
although the apparent number decreased in 2015 prob-
ably due to a major change in data collection and aggregation.
When compared with the data of 2015 [1] and of 2006 [2],
the number of operations in 2016 for congenital heart disease
decreased by 3.4% (8744 vs. 9054) and 7.6%, respectively; that
for valvular heart disease increased by 16.1% (23,012 vs.
19,820) and 52.5%, respectively; that for thoracic aortic
aneurysm increased by 9.4% (19,078 vs. 17,444) and 104.6%,
respectively; that for ischemic heart decreased by 1.5% (14,874
vs. 15,103) and 21.1%, respectively; that for other cardiovas-
cular procedures decreased slightly by 1.1% (1874 vs. 1895)
and increased by 64.1%, respectively. Data for individual cat-
egories are summarized in Tables 3, 4, 5, 6, 7, 8.
Table 1 Number of institutions involved in the survey
Questionnaires
Sent
out
Responded Response rate
(%)
(A) Cardiovascular
surgery
– – –
(B) General thoracic
Surgery
744 693 93.1
(C) Esophageal surgery 584 543 93.0
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Fig. 1 Cardiovascular surgery. IHD
ischemic heart disease
Table 2 Categories subclassified according to the number of opera-
tions performed
Number of operations performed Category
General thoracic surgery
0 5
1–24 52
25–49 119
50–99 185
100–149 130
150–199 89
C 200 113
Total 693
Number of operations performed Esophageal surgery
0 70
1–4 138
5–9 107
10–19 95
20–29 41
30–39 26
40–49 22
C 50 44
Total 543
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In 2016, of 8744 operations for congenital heart disease,
6462 open-heart surgeries were performed with overall
hospital mortality of 2.2%. The number of operations
decreased gradually throughout these 10 years (maximum
7386 cases in 2006), and overall hospital mortality showed a
plateau at around 3.0%. In detail, the most common disease
was ventricular septal defect (VSD) (perimembra-
nous/muscular) (1232 cases), as in 2015 when VSD became
the most common disease for the first time since the inau-
guration of this survey. Atrial septal defect (ASD) was the
‘‘second’’ most common one (1032 cases) in 2016. It was
mainly due to the development and increasing use of com-
mercially available catheter devices for ASD closure. In the
last 10 years, hospitalmortality for complex congenital heart
disease was as follows (2006 [2], 2011 [3], and 2016),
complete atrio-septal defect (4.5%, 4.7%, and 3.5%),
tetralogy of Fallot (1.9%, 0.7%, and 1.6%), transposition of
the great arteries with intact septum (4.4%, 2.5%, and 4.4%)
and with ventricular septal defect (9.1%, 3.6%, and 8.3%),
single ventricle (6.7%, 4.4%, and 5.1%), and hypoplastic left
heart syndrome (16.6%, 14.3%, and 7.5%). Right heart
bypass surgery is now commonly performed (405 bidirec-
tional Glenn procedures excluding 48 Damus–Kaye–Stansel
procedures and 410 Fontan-type procedures including total
cavo-pulmonary connection) with acceptable hospital mor-
tality (1.5% and 2.2%, respectively). The Norwood type I
procedure was performed in 20 cases, with a relatively low
hospital mortality rate of 15%.
The total number of operations for valvular heart disease
is increasing, although the apparent number dropped in the
survey in 2015, probably because of a major change in the
process of data collection. The number of isolated aortic
valve replacements/repairs with/without CABG (n = 9472)
increased by 9.5% from the previous year (8651) and by
10.3% from 5 years ago (n = 8589), although trans-cathe-
ter aortic valve replacement (TAVR or TAVI) was intro-
duced in 2013 and is rapidly spreading.
The hospital mortality of single valve placement was
3.1% and 6.3% for the aortic and mitral positions, while that
for mitral valve repair was only 1.5%. The hospital mortality
for redo valve surgery was 7.1% in the aortic and 8.2% in the
mitral positions, respectively. Finally, overall hospital
mortality did not show a dramatic improvement over the last
10 years (4.0% in 2006 [2], 3.4% in 2011 [3], and 3.5% in
2016), which might be partially due to the recent increasing
age of the patients. Repair of the valve became a common
procedure (367 cases of aortic, 6711 cases of mitral, and
5400 cases tricuspid), and mitral valve repair constituted
29.2%of all valvular operations and 64.4%of allmitral valve
procedures, which are similar to those of the last 5 years.
Aortic and mitral valve replacements with bioprostheses
were performed in 9693 cases and 2499 cases, respectively.
The ratio of bioprostheses was 81.9% in the aortic and 65.2%Ta
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in the mitral positions. This ratio of using bioprostheses
increased dramatically from 30 to 40% in the early 2000s
[4, 5]. CABG was performed as a concomitant procedure in
18.5% of all valvular operations (15.1% in 2006 [2] and
17.5% in 2011 [3]).
Isolated CABG was performed in 13,654 cases, only
76.1% of that 10 years ago (n = 17,941) [2]. Among these,
off-pump CABG was intended in 8554 cases (62.6%), with
a success rate of 97.3%, so that the final success rate of off-
pump CABG was 60.9%. The percentage of intended off-
pump CABG reached 60.3% in 2004 [4], and it was then
kept at over 60% until now. In 13,654 isolated CABG
patients, 13,029 patients (95.4%) received at least one
arterial graft, while all-arterial-graft CABG was performed
in only 3103 patients or 22.7% of them. The operative and
hospital mortality rates associated with primary elective
CABG procedures in 11,154 cases were 0.9% and 1.6%,
respectively. A similar data analysis of CABG including
primary/redo and elective/emergency data was begun in
2003 [5], and the operative and hospital mortality rates
associated with primary elective CABG procedures in 2003
were 1.0% and 1.5%, respectively, so that the operative
results of primary CABG have been stable. Hospital mor-
tality of primary emergency CABG in 2318 cases was still
high, at 6.9%. The conversion from off-pump CABG rate
was 2.7%, with hospital mortality of 9.9%. A total of 1220
patients underwent surgery for complications of myocar-
dial infarction, including 675 operations for left ventricular
aneurysm, ventricular septal perforation, or cardiac rupture
and 395 operations for ischemic mitral regurgitation. In this
report, the number of concomitant coronary artery bypass
grafting (CABG) procedures with other major procedures
is not included in the category of ischemic heart disease but
in other categories such as valvular heart disease and tho-
racic aneurysm; then, the overall number of CABG pro-
cedure including concomitant CABG with other major
procedures still remained at over 20,000 cases per year
(20,589 cases) in 2016.
Operations for arrhythmia were performed mainly as a
concomitant procedure in 7168 cases, with a 24.3%
increase compared with that of 2015. Implantations of
pacemakers and ICDs are not included in this category.
The hospital mortality of arrhythmia surgery including
3974 MAZE procedures was 3.4%. The MAZE procedure
has become a quite common procedure (2944 cases in 2006
[2], and 3771 cases in 2011 [3]).
In 2016, 19,078 operations were performed for diseases
of the thoracic and thoracoabdominal aortae: 9441 for
aortic dissection and 9637 for non-dissection. The number
of operations for aortic dissection increased by 10.5% this
year compared with the previous year (n = 8547). The
hospital mortality of operations for 5461 Stanford type A
acute aortic dissections remained as high as 11.3%. The
number of operations for non-dissected aneurysm increased
by 8.3%, with overall hospital mortality of 5.7% (4.3% and
21.2% for unruptured and ruptured aneurysms,
respectively).
The number of stent graft procedures has recently
increased remarkably. Most importantly, the number of
open stent grafts with total arch replacement strikingly
increased 5 times (228–1155) and 3.4 times (308–1048) in
dissecting and non-dissecting aortic aneurysms, respec-
tively. This must be associated with the commercial
Table 6 Pulmonary thromboembolism (total; 138)
Cases 30-Day mortality Hospital
mortality
Hospital After discharge
Acute 90 10 (11.1) 11
Chronic 48 2 (4.2) 3
Total 138 12 (8.7) 0 14 (10.1)
(), % mortality
Table 7 Implantation of VAD (total; 164)
Cases 30-Day mortality Hospital
mortality
Hospital After
discharge
Implantation of VAD 164 3 (1.8) 3 (1.8) 31 (18.9)
(), % mortality
VAD ventricular assist devise
Table 8 Heart transplantation (total; 51)
Cases 30-Day mortality Hospital
mortality
Hospital After discharge
Heart transplantation 51 1 (2.0) 0 2 (3.9)
Heart and lung
transplantation
0 0 0 0
Total 51 1 (2.0) 0 2 (3.9)
(), % mortality
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availability of special designed device for open stent
grafting since 2014.
A total of 3287 patients with aortic dissection underwent
stent graft placement: 2052 thoracic endovascular aortic
repair (TEVAR) and 1235 open stent grafting. The number
of TEVAR procedures for type B chronic aortic dissections
increased by 41.4% from 1065 cases in 2015 to 1506 cases
in 2016. The hospital mortality rates associated with
TEVAR for type B aortic dissection were 9.6% and 2.1%
in acute and chronic cases, respectively.
A total of 4257 patients with non-dissected aortic
aneurysms underwent stent graft placement, consisting of
3063 TEVAR [5.2% increase compared with 2015
(n = 2912)] and 1194 open stent grafts [27.4% increase
compared with 2015 (n = 937)]. The hospital mortality
rates for TEVAR and open stenting were as follows:
TEVAR, 3.7% for unruptured and 21.4% for ruptured
aneurysms; open stent grafting, 6.1% for unruptured and
17.9% for ruptured aneurysms.
(B) General thoracic surgery
The 2016 survey of general thoracic surgery comprised 693
surgical units, and most data were submitted through the
web-based collection system of the national clinical data-
base (NCD) [6]. In total, 82,193 operations were reported
by general thoracic surgery departments in 2016, 1.9 times
the number of operations in 2001 and 2418 more opera-
tions than in 2015, while the number of surgical units
submitting reports to this survey decreased by 43 due to
conversion of the data collection system since 2014
(Fig. 2).
In 2016, 42,107 operations for primary lung cancer were
performed (Table 9), and the number has increased every
year. The 2016 value is 2.2 times that of 2001. Operations
for lung cancer accounted for 51.2% of all procedures in
general thoracic surgery.
Table 9 Total cases of general thoracic surgery during 2016
Cases %
Benign pulmonary tumor 2124 2.6
Primary lung cancer 42,107 51.2
Other primary malignant pulmonary tumor 375 0.5
Metastatic pulmonary tumor 8497 10.3
Tracheal tumor 122 0.1
Mesothelioma 634 0.8
Chest wall tumor 664 0.8
Mediastinal tumor 5026 6.1
Thymectomy for MG without thymoma 145 0.2
Inflammatory pulmonary disease 2142 2.6
Empyema 2833 3.4
Bullous disease excluding pneumothorax 436 0.5
Pneumothorax 14,867 18.1
Chest wall deformity 189 0.2
Diaphragmatic hernia including traumatic 37 0.0
Chest trauma excluding diaphragmatic hernia 426 0.5
Lung transplantation 75 0.1
Others 1494 1.8
Total 82,193 100.0
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The number of video-assisted thoracic surgery (VATS)
operations, defined as a surgical procedure using a skin
incision longer than 8 cm and/or a minithoracotomy (hy-
brid) approach, has been described since the Annual Report
2015. The number of VATS operations for benign pul-
monary tumor, primary lung cancer, and the total number
of VATS operations in 2016 are shown in Tables 10, 11,
13, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, and 29,
respectively.
There were 2124 operations for benign pulmonary
tumors in 2016, similar to the number in 2015 (Table 10).
Hamartoma was the most frequent diagnosis in operations
for benign pulmonary tumors. VATS was performed in
2015 patients (94.7%).
Additional information on primary malignant pul-
monary tumors is shown in Tables 11 and 12. With regard
to lung cancer subtype, adenocarcinoma was by far the
most frequent diagnosis (70.3% of all lung cancer opera-
tions), followed by squamous cell carcinoma (18.7%).
Sublobar resection was performed in 10,666 lung cancer
Table 11 Primary malignant pulmonary tumor
Cases 30-Day mortality Hospital
mortality
VATS
Hospital After
discharge
Primary malignant pulmonary tumor 42,482 118
(0.3)
52 (0.1) 242 (0.6) 28,568
Lung cancer 42,107 115
(0.3)
52 (0.1) 237 (0.6) 28,568
Adenocarcinoma 29,607 53 (0.2) 24 (0.1) 96 (0.3)
Squamous cell carcinoma 7877 40 (0.5) 17 (0.2) 102 (1.3)
Large cell carcinoma 791 1 (0.1) 4 (0.5) 5 (0.6)
(LCNEC) 480 0 2 (0.4) 2 (0.4)
Small cell carcinoma 755 6 (0.8) 2 (0.3) 10 (1.3)
Adenosquamous carcinoma 574 6 (1.0) 1 (0.2) 8 (1.4)
Carcinoma with pleomorphic,
sarcomatoid or sarcomatous
elements
468 4 (0.9) 1 (0.2) 7 (1.5)
Carcinoid 251 0 1 (0.4) 0
Carcinomas of salivary-gland type 33 0 0 0
Unclassified 59 0 0 0
Multiple lung cancer 1327 3 (0.2) 1 (0.1) 7 (0.5)
Others 365 2 (0.5) 1 (0.3) 2 (0.5)
Wedge resection 6275 8 (0.1) 9 (0.1) 19 (0.3) 5395
Segmental excision 4391 8 (0.18) 1 (0.0) 13 (0.3) 3265
(Sleeve segmental excision) 16 0 0 0 5
Lobectomy 30,597 86 (0.3) 37 (0.1) 176 (0.6) 19,697
(Sleeve lobectomy) 481 3 (0.6) 1 (0.2) 7 (1.5) 92
Pneumonectomy 477 8 (1.7) 3 (0.6) 22 (4.6) 39
(Sleeve pneumonectomy) 15 1 (6.7) 0 5 (33.3) 2
Other bronchoplasty 48 1 (2.1) 0 1 (2.1) 0
Pleuropneumonectomy 3 1 (33.3) 0 1 (33.3) 0
Others 316 3 (0.9) 2 (0.6) 5 (1.6) 172
Unknown 0 0 0 0
Sarcoma 49 1 (2.0) 0 2 (4.1)
AAH 131 0 0 0
Others 195 2 (1.0) 0 3 (1.5)
(), Mortality %
Table 10 Benign pulmonary tumor
Cases 30-Day mortality Hospital
mortality
by
VATS
Hospital after
discharge
Benign pulmonary tumor
Hamartoma 442 0 0 1 (0.2) 423
Sclerosing
hemangioma
96 0 0 0 94
Papilloma 17 0 0 0 16
Mucous gland
adenoma
bronchial
6 0 0 0 5
Fibroma 118 0 1 (0.8) 0 110
Lipoma 10 0 0 0 7
Neurogenic tumor 15 0 0 0 13
Clear cell tumor 5 0 0 0 5
Leiomyoma 15 0 0 0 14
Chondroma 7 0 0 0 6
Inflammatory
myofibroblastic
tumor
2 0 0 0 2
Pseudolymphoma 39 0 0 0 37
Histiocytosis 9 0 0 0 8
Teratoma 6 0 0 0 5
Others 1337 0 0 1 (0.1) 1270
Total 2124 0 1 (0.05) 2 (0.1) 2015
(), Mortality %
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cases (25.1% of all cases), and lobectomy was performed
in 30,597 cases (72.0% of all cases). Sleeve lobectomy was
performed in 481 cases, and pneumonectomy was required
in 477 cases (1.1% of all cases). VATS lobectomy for lung
cancer was performed in 19,697 cases (64.3% of all
lobectomy cases). The number of VATS procedures for
primary lung cancer was slightly higher than in 2015. The
number of patients aged 80 years or older who underwent
lung cancer surgery was 5279 (12.5%). In total, 115
patients died before hospital discharge within 30 days after
surgery, and 52 patients died after discharge within 30 days
after surgery. Therefore, 167 patients died within 30 days
after surgery (30-day mortality rate, 0.4%). In total, 237
patients died before discharge (hospital mortality rate,
0.6%), and the 30-day mortality rate, by procedure, was
0.3% for segmentectomy, 0.6% for lobectomy, and 4.6%
for pneumonectomy. Interstitial pneumonia was the leading
cause of death after lung cancer surgery, followed by
pneumonia, cardiovascular events, and respiratory failure.
The risk calculators for mortality and morbidity, such as
broncho-pleural fistula and respiratory failure, after lung
cancer surgery based on the NCD are now available [7, 8].
Operations for metastatic pulmonary tumors are shown
in Table 13; 8497 operations were performed in 2016.
Colorectal cancer was the most frequent diagnosis (47.7%
of all cases).
There were 122 operations for malignant tracheal tumor
in 2016, but only 29 patients were treated with curative
intent (Table 14).
There were 634 pleural tumors in 2016 (Table 15).
Diffuse malignant pleural mesothelioma was the most
frequent histologic diagnosis. Total pleurectomy was per-
formed in 73 cases, and extrapleural pneumonectomy was
performed in 64 cases. The hospital mortality rate was 0%
after total pleurectomy and 1.6% after extrapleural pneu-
monectomy, which were better than the previous outcomes.
In total, 664 chest wall tumors were resected in 2016
(Table 16), of which 346 (52.1%) were benign. Among the
318 malignant chest wall tumors, 207 (65.1%) were
metastatic tumors.
Table 12 Details of lung cancer operations
TNM
c-Stage Cases
Ia 25,963
Ib 7947
IIa 3149
IIb 1796
IIIa 2459
IIIb 175
IV 441
NA 177
Total 42,107
Sex Cases
Male 25,716
Female 16,391
NA 0
Total 42,107
Cause of death Cases
Cardiovascular 32
Pneumonia 42
Pyothorax 3
Bronchopleural fistula 18
Respiratory failure 29
Pulmonary embolism 2
Interstitial pneumonia 84
Brain infarction or bleeding 6
Others 62
Unknown 11
Total 289
p-Stage Cases
0 (pCR) 634
Ia 22,249
Ib 8334
IIa 3354
IIb 2131
IIIa 4029
IIIb 180
IV 1013
NA 183
Total 42,107
Age (years) Cases
\ 20 32
20–29 45
30–39 233
40–49 1154
50–59 3710
Table 12 (continued)
Age (years) Cases
60–69 14,181
70–79 17,491
80–89 5187
C 90 74
NA 0
Total 42,107
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Table 13 Metastatic pulmonary
tumor
Cases 30-Day mortality Hospital mortality VATS
Hospital After discharge
Metastatic pulmonary tumor 8497 11 (0.1) 9 (0.1) 20 (0.2) 7909
Colorectal 4052 4 (0.1) 3 (0.1) 8 (0.2) 3766
Hepatobiliary/pancreatic 400 1 (0.3) 0 1 (0.3) 381
Uterine 431 1 (0.2) 0 1 (0.2) 410
Mammary 472 0 1 (0.2) 0 444
Ovarian 69 0 0 0 64
Testicular 61 0 0 0 57
Renal 724 0 0 1 (0.1) 688
Skeletal 140 0 0 0 130
Soft tissue 213 0 0 0 192
Otorhinolaryngological 459 2 (0.4) 1 (0.2) 2 (0.4) 430
Pulmonary 549 1 (0.2) 2 (0.4) 3 (0.5) 471
Others 927 2 (0.2) 2 (0.2) 4 (0.4) 876
(), Mortality %
Table 14 Tracheal tumor
Cases 30-Day mortality
Hospital After discharge Hospital mortality
Tracheal tumor 122 4 (3.3) 0 5 (4.1)
A. Primary malignant tumor
Histological classification
Squamous cell carcinoma 15 0 0 1 (6.7)
Adenoid cystic carcinoma 20 1 (5.0) 0 1 (5.0)
Mucoepidermoid carcinoma 0 0 0 0
Others 11 0 0 0
Total 46 1 (2.2) 0 2 (4.3)
B. Metastatic/invasive malignant tumor
e.g. invasion of thyroid cancer 36 3 (8.3) 0 3 (8.3)
C. Benign tracheal tumor
Histological classification
Papilloma 6 0 0 0
Adenoma 2 0 0 0
Neurofibroma 0 0 0 0
Chondroma 0 0 0 0
Leiomyoma 4 0 0 0
Others 28 0 0 0
Histology unknown 0 0 0 0
Total 40 0 0 0
Operation
Sleeve resection with reconstruction 27 0 0 0
Wedge with simple closure 0 0 0 0
Wedge with patch closure 1 0 0 0
Total laryngectomy with tracheostomy 1 0 0 0
Others 4 1 (25.0) 0 1 (25.0)
Unknown 0 0 0 0
Total 33 1 (3.0) 0 1 (3.0)
(), Mortality %
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Mediastinal tumors were resected in 5026 patients, a
slight increase from the previous year (Table 17). Thymic
epithelial tumor, including 1986 thymomas, 314 thymic
carcinomas, and 40 thymic carcinoids, was the most fre-
quent mediastinal tumor type in 2016.
Thymectomy for myasthenia gravis was performed in
478 patients (Table 18); 333 operations were associated
with thymoma, and the remaining were not associated with
thymoma.
Operations for non-neoplastic disease were performed in
22,424 patients. There were 2142 cases of lung resection
for inflammatory lung diseases (Table 19); 21.7% of the
cases were associated with atypical mycobacterium infec-
tions, and 15.2% were fungal infections. An operation for
inflammatory nodules was performed because lung cancer
was suspected before surgery in 913 cases (42.6%)
The 2833 operations for empyema (Table 20) included
2085 cases (73.6%) of acute empyema and 748 cases of
chronic empyema. A bronchopleural fistula was reported in
470 patients with acute empyema and 359 patients with
chronic empyema. The hospital mortality rate was 18.3%
in patients with acute empyema with fistula.
There were 100 operations for descending necrotizing
mediastinitis (Table 21). The hospital mortality rate was
14.0%.
There were 436 operations for bullous diseases
(Table 22). Lung volume reduction surgery was performed
in only 18 patients.
A total of 14,867 operations were performed for spon-
taneous pneumothorax (Table 23). The 11,835 operations
for primary pneumothorax included 3028 patients (25.6%)
who underwent bullectomy only and 7966 patients (67.3%)
who underwent an additional procedure. There were 3032
Table 16 Chest wall tumor
Cases 30-Day mortality Hospital mortality VATS
Hospital After discharge
Chest wall tumor
Primary malignant tumor 111 0 0 0 54
Metastatic malignant tumor 207 1 (0.5) 0 2 (1.0) 93
Benign tumor 346 0 0 0 267
Total 664 1 (0.2) 0 2 (0.3) 414
(), Mortality %
Table 15 Tumor of pleural
origin
Histological classification Cases 30-Day mortality Hospital mortality
Hospital After discharge
Tumor of pleural origin
Solitary fibrous tumor 122 0 0 0
Diffuse malignant pleural mesothelioma 247 1 (0.4) 0 2 (0.8)
Localized malignant pleural mesothelioma 42 0 0 0
Others 223 4 (1.8) 1 (0.4) 8 (3.6)
Total 634 5 (0.8) 1 (0.2) 10 (1.6)
Operative procedure Cases 30-Day mortality Hospital mortality
Hospital After discharge
Extrapleural pneumonectomy 64 0 0 1 (1.6)
Total pleurectomy 73 0 0 0
Others 110 1 (0.9) 0 1 (0.9)
Total 247 1 (0.4) 0 2 (0.8)
(), Mortality %
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operations for secondary pneumothorax. COPD was by far
the most prevalent associated disease (70.7%). The hospital
mortality rate for secondary pneumothorax associated with
COPD was 2.8%.
The 2016 survey reported 181 operations for chest wall
deformity (Table 24). However, this might be an under-
estimate, because the Nuss procedure for pectus excavatum
was more likely to have been performed in pediatric sur-
gery centers not associated with JATS.
Table 19 Operations for non-neoplastic diseases
Cases 30-Day mortality Hospital mortality
Hospital After discharge
Operations for non-neoplastic diseases 22,424 195 (0.9) 20 (0.1) 466 (2.1)
Cases 30-Day mortality Hospital mortality VATS
Hospital After discharge
A. Inflammatory pulmonary disease 2142 6 (0.3) 1 (0.0) 16 (0.7) 1948
Tuberculous infection 41 0 0 0 38
Mycobacterial infection 464 0 0 3 (0.6) 423
Fungal infection 326 1 (0.3) 1 (0.3) 4 (1.2) 255
Bronchiectasis 58 0 0 0 47
Tuberculous nodule 88 0 0 0 83
Inflammatory pseudotumor 774 3 (0.4) 0 4 (0.5) 751
Interpulmonary lymph node 51 0 0 0 50
Others 340 2 (0.6) 0 5 (1.5) 301
(), Mortality %
Table 17 Mediastinal tumor
Cases 30-Day mortality Hospital mortality By VATS
Hospital After discharge
Mediastinal tumor 5026 6 (0.1) 3 (0.06) 9 (0.2) 3636
Thymoma 1986 2 (0.1) 2 (0.1) 2 (0.1) 1218
Thymic cancer 314 2 (0.6) 1 (0.3) 2 (0.6) 164
Thymus carcinoid 40 0 0 0 20
Germ cell tumor 84 0 0 0 47
Benign 56 0 0 0 34
Malignant 28 0 0 0 13
Neurogenic tumor 447 0 0 0 419
Congenital cyst 1111 0 0 0 993
Goiter 81 0 0 1 (1.2) 31
Lymphatic tumor 182 2 (1.1) 0 2 (1.1) 136
Excision of pleural recurrence of thymoma 31 0 0 0 27
Thymolipoma 22 0 0 0 17
Others 728 0 0 2 (0.3) 564
(), Mortality %
Table 18 Thymectomy for myasthenia gravis
Cases 30-Day mortality Hospital
mortality
by
VATS
Hospital After
discharge
Thymectomy for
myasthenia
gravis
478 2 (0.4) 1 (0.2) 2 (0.4) 276
With thymoma 333 2 (0.6) 1 (0.3) 2 (0.6) 189
(), Mortality %
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Diaphragmatic hernia was treated surgically in 37
patients (Table 25). This figure might be an underestimate,
since some procedures might have been classified as gas-
trointestinal surgery.
The survey reported 426 procedures for chest trauma
excluding iatrogenic injuries (Table 26). The hospital
mortality rate was 7.3%.
Table 22 D. Bullous diseases
Cases 30-Day mortality Hospital mortality VATS
Hospital After discharge
D. Bullous diseases 436 2 (0.5) 0 3 (0.7) 405
Emphysematous bulla 354 0 0 1 (0.3) 331
Bronchogenic cyst 15 0 0 0 14
Emphysema with LVRS 18 0 0 0 17
Others 49 2 (4.1) 0 2 (4.1) 43
(), Mortality %
LVRS lung volume reduction surgery
Table 20 B. Empyema
Cases 30-Day mortality Hospital mortality by VATS
Hospital After discharge
Acute empyema 2085 50 (2.4) 5 (0.2) 150 (7.2) 1758
With fistula 470 24 (5.1) 1 (0.2) 86 (18.3) 272
Without fistula 1596 26 (1.6) 4 (0.3) 63 (3.9) 1469
Unknown 19 0 0 1 (5.3) 17
Chronic empyema 748 19 (2.5) 2 (0.3) 45 (6.0) 442
With fistula 359 15 (4.2) 2 (0.6) 26 (7.2) 160
Without fistula 355 4 (1.1) 0 16 (4.5) 257
Unknown 34 0 0 3 (8.8) 25
Total 2833 69 (2.4) 7 (0.2) 195 (6.9) 2200
(), Mortality %
Table 21 C. Descending necrotizing mediastinitis
Cases 30-Day mortality Hospital mortality VATS
Hospital After discharge
C. Descending necrotizing mediastinitis 100 7 (7.0) 0 14 (14.0) 71
(), Mortality %
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Table 23 E. Pneumothorax
Cases 30-Day mortality Hospital mortality
Hospital After discharge
14,867 57 (0.4) 11 (0.1) 129 (0.9)
Spontaneous pneumothorax
Operative procedure Cases 30-Day mortality Hospital mortality VATS
Hospital After discharge
Bullectomy 3028 2 (0.1) 1 (0.0) 8 (0.3) 2986
Bullectomy with additional procedure 7966 9 (0.11) 0 12 (0.2) 7860
Coverage with artificial material 7564 7 (0.09) 0 9 (0.1) 7461
Parietal pleurectomy 53 1 (1.9) 0 1 (1.9) 52
Coverage and parietal pleurectomy 73 1 (1.4) 0 1 (1.4) 73
Others 276 0 0 1 (0.4) 274
Others 836 6 (0.7) 1 (0.1) 11 (1.3) 771
Unknown 5 0 0 0 5
Total 11,835 17 (0.1) 2 (0.02) 31 (0.3) 11,622
Secondary pneumothorax
Associated disease Cases 30-Day mortality Hospital mortality VATS
Hospital After discharge
COPD 2145 20 (0.9) 5 (0.2) 59 (2.8) 2068
Tumorous disease 124 8 (6.5) 2 (1.6) 15 (12.1) 114
Catamenial 166 0 0 0 166
LAM 38 0 0 0 38
Others (excluding pneumothorax by trauma) 559 12 (2.1) 2 (0.4) 24 (4.3) 520
Unknown 0 0 0 0 0
Operative procedure Cases 30 Day mortality Hospital mortality VATS
Hospital After discharge
Bullectomy 433 4 (0.9) 1 (0.2) 8 (1.8) 417
Bullectomy with additional procedure 1828 17 (0.9) 4 (0.2) 42 (2.3) 1779
Coverage with artificial material 1736 16 (0.9) 4 (0.2) 38 (2.2) 1689
Parietal pleurectomy 6 0 0 0 5
Coverage and parietal pleurectomy 23 0 0 2 (8.7) 23
Others 63 1 (1.6) 0 2 (3.2) 62
Others 768 19 (2.5) 4 (0.5) 48 (6.3) 707
Unknown 3 0 0 0 3
Total 3032 40 (1.3) 9 (0.3) 98 (3.2) 2906
(), Mortality %
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Table 27 shows operations for other diseases, including
81 cases of arteriovenous malformation and 113 cases of
pulmonary sequestration.
A total of 75 lung transplantations were performed in
2016 (Table 28): 58 patients received lung transplants from
brain-dead donors and 17 received transplants from living-
Table 24 F. Chest wall deformity
Cases 30-Day mortality Hospital
mortality
Hospital After
discharge
F. Chest wall
deformity
181 0 0 0
Funnel chest 8 0 0 0
Others 7 0 0 0
(), Mortality %
Table 25 G. Diaphragmatic hernia
Cases 30-Day mortality Hospital
mortality
VATS
Hospital After
discharge
G.
Diaphragmatic
hernia
37 0 0 0 19
Congenital 9 0 0 0 8
Traumatic 13 0 0 0 6
Others 15 0 0 0 5
(), Mortality %
Table 26 H. Chest trauma
Cases 30-Day mortality Hospital
mortality
VATS
Hospital After
discharge
H. Chest
trauma
426 26 (6.1) 0 31 (7.3) 277
(), Mortality %
Table 27 I. Other respiratory surgery
Cases 30-Day mortality Hospital
mortality
VATS
Hospital After
discharge
I. Other
respiratory
surgery
1394 28 (2.0) 1 (0.1) 78 (5.6) 1008
Arteriovenous malformation 81 0 0 1 (1.2) 78
Pulmonary sequestration 113 0 0 0 95
Postoperative bleeding  air leakage 428 15 (3.5) 1 (0.2) 40 (9.3) 292
Chylothorax 67 1 (1.5) 0 2 (3.0) 55
Others 705 12 (1.7) 0 35 (5.0) 488
(), Mortality %
Table 28 Lung transplantation
Cases 30-Day mortality Hospital
mortality
Hospital After
discharge
Single lung transplantation
from brain-dead donor
29 0 0 1 (3.4)
Bilateral lung
transplantation from
brain-dead donor
29 0 0 2 (6.9)
Lung transplantation from
living donor
17 1 (5.9) 0 2 (11.8)
Total lung transplantation 75 1 (1.3) 0 5 (6.7)
Donor of living donor lung
transplantation
33 0 0 0
(), Mortality %
Table 29 Video-assisted thoracic surgery
Cases 30-Day mortality Hospital
mortality
Hospital After
discharge
Video-assisted
thoracic surgery
64,036 191
(0.3)
58 (0.09) 424 (0.7)
(), Mortality %
(including thoracic sympathectomy 160)
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related donors. The number of lung transplantation proce-
dures has increased slightly.
The number of VATS procedures has increased annu-
ally, reaching 64,036 (77.9% of all general thoracic surg-
eries) in 2016 (Table 29).
The details of tracheobronchoplasty, pediatric surgery,
and combined resection of neighboring organs are shown in
Tables 30, 31, and 32, 33.
Table 30 Tracheobronchoplasty
Cases 30-Day mortality Hospital
mortality
Hospital After
discharge
Tracheobronchoplasty 790 11 (1.4) 1 (0.1) 26 (3.3)
Trachea 41 1 (2.4) 0 1 (2.4)
Sleeve resection with reconstruction 32 0 0 0
Wedge with simple closure 2 0 0 0
Wedge with patch closure 1 0 0 0
Total laryngectomy with tracheostomy 1 0 0 0
Others 5 1 (20.0) 0 1 (20.0)
Carinal reconstruction 22 1 (4.5) 0 1 (4.5)
Sleeve pneumonectomy 17 1 (5.9) 0 5 (29.4)
Sleeve lobectomy 483 2 (0.4) 1 (0.2) 7 (1.4)
Sleeve segmental excision 17 0 0 0
Bronchoplasty without lung resection 26 1 (3.8) 0 3 (11.5)
Others 184 5 (2.7) 0 9 (4.9)
(), Mortality %
Table 31 Pediatric surgery
Cases 30-Day mortality Hospital
mortality
Hospital After discharge
Pediatric surgery 353 2 (0.6) 0 3 (0.8)
(), Mortality %
Table 32 Combined resection of neighboring organ(s)
Cases 30-Day mortality Hospital
mortality
Hospital After
discharge
Combined resection of
neighboring organ(s)
1396 5 (0.4) 6 (0.4) 20 (1.4)
Organ resected Cases 30-Day mortality Hospital
mortality
Hospital After
discharge
A. Primary lung cancer
Aorta 12 0 0 0
Superior vena cava 29 1 (3.4) 0 2 (6.9)
Brachiocephalic vein 7 0 0 0
Pericardium 102 2 (2.0) 1 (1.0) 3 (2.9)
Pulmonary artery 103 0 0 3 (2.9)
Left atrium 17 0 0 2 (11.8)
Diaphragm 62 1 (1.6) 1 (1.6) 4 (6.5)
Chest wall (including
ribs)
347 1 (0.3) 2 (0.6) 4 (1.2)
Vertebra 16 0 0 1 (6.3)
Esophagus 4 0 0 0
Total 699 5 (0.7) 4 (0.6) 19 (2.7)
B. Mediastinal tumor
Aorta 6 0 0 0
Superior vena cava 68 0 0 0
Brachiocephalic vein 122 1 (0.8) 1 (0.8) 1 (0.8)
Pericardium 358 1 (0.3) 1 (0.3) 2 (0.6)
Pulmonary artery 5 0 0 0
Left atrium 0 0 0 0
Diaphragm 47 0 1 (2.1) 0
Chest wall (including
ribs)
8 0 0 0
Vertebra 4 0 0 0
Esophagus 8 0 0 0
Lung 524 1 (0.2) 2 (0.4) 2 (0.4)
Total 1150 3 (0.3) 5 (0.4) 5 (0.4)
(), Mortality %
Table 33 Operation of lung cancer invading the chest wall of the
apex
Cases 30-Day mortality Hospital
mortality
Hospital After
discharge
Operation of lung cancer
invading the chest wall
of the apex
754 3 (0.4) 2 (0.3) 7 (0.9)
(), Mortality %
Includes tumors invading the anterior apical chest wall and posterior
apical chest wall (superior sulcus tumor, so called Pancoast type)
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(C) Esophageal surgery
During 2016 alone, a total of 12,753 patients with eso-
phageal diseases were registered from 543 institutions
(response rate: 93.0%) affiliated to the Japanese Associa-
tion for Thoracic Surgery and/or to the Japan Esophageal
Society. Among these institutions, those where 20 or more
patients underwent esophageal surgeries within 2016 were
133 institutions (24.5%), which shows no definite shift of
esophageal operations to high-volume institutions when
compared to the data of 2015 (23.8%) (Table 34). Of 2418
patients with a benign esophageal disease, 1525 (63.1%)
patients underwent surgery, and 73 (3.0%) patients
underwent endoscopic resection, while 820 (33.9%)
patients did not undergo any surgical treatment (Table 35).
Of 10,830 patients with a malignant esophageal tumor,
8296 (76.6%) patients underwent resection, with
esophagectomy for 6158 (56.9%) and endoscopic mucosal
resection (EMR) or endoscopic submucosal dissection
(ESD) for 2138 (19.7%), while 2534 (23.4%) patients did
not undergo any resection (Tables 36, 37). The annual
trend of registered in-patients with esophageal diseases has
not changed in the last decades (Fig. 3).
Among benign esophageal diseases (Table 35), hiatal
hernia, achalasia, esophageal varices, and esophagitis (in-
cluding reflux esophagitis) were the most common condi-
tions in Japan. On the other hand, benign esophageal
tumors, spontaneous rupture of the esophagus, and con-
genital esophageal atresia were common diseases that were
surgically treated, as well as the above-mentioned diseases.
Open surgery was performed in 1030 (67.5%) patients with
a benign esophageal disease, with 30-day mortality in 6
(0.6%), while thoracoscopic and/or laparoscopic surgery
was performed for 495 (32.5%) patients, with no 30-day
mortality. The difference in these death rates between open
and endoscopic surgery seems to be related the conditions
requiring open surgery.
The majority of malignant diseases were carcinomas
(Table 36). Among esophageal carcinomas, the incidence
of squamous cell carcinoma was 89.6%, while that of
adenocarcinomas including Barrett’s cancer was 7.8%. The
resection rate for patients with a squamous cell carcinoma
was 75.3%, while that for patients with an adenocarcinoma
was 89.7%.
According to location, cancer in the thoracic esophagus
was the most common (Table 37). Of the 4305 patients
(40.0% of all esophageal malignancies) having superficial
esophageal cancers within mucosal and submucosal layers,
6158 (56.9%) patients underwent esophagectomy, while
2138 (19.7%) patients underwent EMR or ESD. The
30-day mortality rate and hospital mortality rate after
esophagectomy for patients with a superficial cancer were
0.4% and 0.8%, respectively.
Multiple primary cancers were observed in 2068
(19.1%) of the 10,830 patients with esophageal cancer.
Synchronous cancer was found in 1008 (9.3%) patients,
while metachronous cancer was observed in 1060 (9.8%)
patients. The stomach, and head and neck region are the
common sites for both synchronous and metachronous
malignancies (Table 37).
Among esophagectomy procedures, transthoracic
esophagectomy through right thoracotomy was the most
commonly performed for patients with a superficial cancer,
as well as for those with an advanced cancer (Table 38).
Transhiatal esophagectomy, commonly performed in
western countries, was performed in only 5.8% of patients
Table 34 Distribution of number of esophageal operations in 2016 in
each institution
Esophageal surgery
Number of
operations in
2016
Benign
esophageal
diseases
Malignant
esophageal
disease
Benign ? malignant
0 241 107 70
1-4 244 138 138
5–9 42 98 107
10–19 9 85 95
20–29 2 34 41
30–39 3 28 26
40–49 1 16 22
C 50 1 37 44
Total 543 543 543
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having a superficial cancer and advanced cancer who
underwent esophagectomy in Japan. Thoracoscopic and/or
laparoscopic esophagectomy was performed for 1296
patients (67.7%) with a superficial cancer and for 2060
patients (48.6%) with an advanced cancer. The number of
cases of thoracoscopic and/or laparoscopic surgery for
superficial or advanced cancer has been increasing for
several years (Fig. 4).
Combined resection of the neighboring organs during
resection of an esophageal cancer was performed in 226
patients (Tables 38, 39). Resection of the aorta together
with esophagectomy was performed in 3 cases. Tracheal
and/or bronchial resection combined with esophagectomy
was performed in 12 patients, with both 30-day mortality
and hospital mortality of 0%. Lung resection combined
with esophagectomy was performed in 56 patients, with
30-day mortality of 0% and hospital mortality of 3.6%.
Salvage surgery after definitive (chemo-) radiotherapy
was performed in 250 patients, with 30-day mortality of
1.6% and hospital mortality of 6.0% (Table 38).
Lastly, we should continue our efforts for complete
surveys through more active collaboration with the Japan
Esophageal Society and other related societies.
Table 36 Malignant esophageal diseases (histologic classification)
Resection (?) Resection (-) Total
Carcinomas 8240 2534 10,774
1 Squamous cell carcinoma 7273 2381 9654
2 Basaloid(-squamous)carcinoma 65 8 73
3 Carcinosarcoma 35 2 37
4 Adenocarcinoma in the Barrett’s esophagus 414 36 450
5 Other adenocarcinoma 343 51 394
6 Adenosquamous carcinoma 26 5 31
7 Mucoepidermoid carcinoma 4 1 5
8 Adenoid cystic carcinoma 0 0 0
9. Endocrine cell carcinoma 53 25 78
10 Undifferentiated carcinoma 8 6 14
11 Others 19 19 38
Other malignancies 43 6 49
1 Malignant non-epithelial tumors 16 0 16
2 Malignant melanoma 23 6 29
3 Other malignant tumors 4 0 4
Not specified 56 0 56
Total 8339 2540 10,879
Resection: including endoscopic resection
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Table 37 Malignant esophageal diseases (clinical characteristics)
Operation (?) EMR or ESD Operation (-) Total
Cases Hospital mortality
B 30 days 31–90 days Total (including after
91 days mortality)
1. Esophageal cancer 6158 40 (0.6) 41 (0.7) 101 (1.6) 2138 2534 10,830
Location
(1) Cervical esophagus 251 1 (0.4) 5 (2.0) 9 (3.6) 100 214 565
(2) Thoracic esophagus 4958 31 (0.6) 33 (0.7) 81 (1.6) 1711 2067 8736
(3) Abdominal esophagus 697 7 (1.0) 1 (0.1) 8 (1.1) 126 125 948
(4) Multiple cancers 251 1 (0.4) 1 (0.4) 2 (0.8) 186 56 493
(5) Others/not described 1 0 1 (100.0) 1 15 72 88
Tumor depth
(A) Superficial cancer(T1) 1913 8 (0.4) 5 (0.3) 15 (0.8) 2124 268 4305
Mucosal cancer (T1a) 361 0 0 0 1857 47 2265
(B) Advanced cancer (T2–T4) 4240 32 (0.8) 36 (0.8) 86 (2.0) 11 2264 6515
(C) Not specified 5 0 0 0 3 2 10
2. Multiple primary cancers 1076 5 (0.5) 11 (1.0) 23 (2.1) 556 436 2068
1) Synchronous 589 1 (0.2) 7 (1.2) 14 (2.4) 210 209 1008
(1) Head and neck 197 0 4 (2.0) 4 (2.0) 82 65 344
(2) Stomach 199 1 (0.5) 1 (0.5) 3 (1.5) 62 57 318
(3) Colorectum 64 0 1 (1.6) 4 (6.3) 20 22 106
(4) Lung 47 0 0 1 (2.1) 13 13 73
(5) Pancreas 4 0 0 0 0 2 6
(6) Liver 5 0 0 1 (20.0) 3 8 16
(7) Others 35 0 0 0 11 24 70
(8) Triple cancers 38 0 1 (2.6) 1 (2.6) 18 18 74
(9) Unknown 0 0 0 0 1 0 1
2) Metachronous 487 4 (0.8) 4 (0.8) 9 (1.8) 346 227 1060
(1) Head and neck 104 1 (1.0) 0 1 (1.0) 130 36 270
(2) Stomach 104 2 (1.9) 3 (2.9) 5 (4.8) 83 53 240
(3) Colorectum 71 1 (1.4) 0 1 (1.4) 24 26 121
(4) Lung 32 0 0 0 13 23 68
(5) Pancreas 0 0 0 0 0 3 3
(6) Liver 3 0 0 0 3 7 13
(7) Others 136 0 1 (0.7) 1 (0.7) 49 52 237
(8) Triple cancers 37 0 0 1 (2.7) 41 27 105
(9) Unknown 0 0 0 0 3 0 3
Unknown 0 0 0 0 0 0 0
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Table 38 Malignant Esophageal diseases (surgical procedures)
Operation (?) Thoracoscopic and/or laparoscopic procedure EMR
or
ESDCases Hospital mortality Cases Hospital mortality
B 30 days 31–90 days Total (including
after 91 days
mortality)
B 30 days 31–90 days Total (including
after 91 days
mortality)
Superficial cancer (T1) 1913 8 (0.4) 5 (0.3) 15 (0.8) 1296 3 (0.2) 4 (0.3) 8 (0.6) 2124
Mucosal cancer (T1a) 361 0 0 0 224 0 0 0 1857
Esophagectomy 1913 8 (0.4) 5 (0.3) 15 (0.8) 1296 3 (0.2) 4 (0.3) 8 (0.6) 2124
(1) Transhiatal
esophagectomy
110 3 (2.7) 0 3 (2.7) 14 0 0 0
(2) Transthoracic (rt.)
esophagectomy and
reconstruction
1645 5 (0.3) 4 (0.2) 11 (0.7) 1229 3 (0.2) 4 (0.3) 8 (0.7)
(3) Transthoracic (lt.)
esophagectomy and
reconstruction
24 0 1 (4.2) 1 (4.2) 0 0 0 0
(4) Cervical esophageal
resection and
reconstruction
47 0 0 0 31 0 0 0
(5) Others 15 0 0 0 5 0 0 0
(6) Esophagectomy
without reconstruction
59 0 0 0 17 0 0 0
(7) not specified 13 0 0 0 0 0 0 0
Advanced cancer (T2–T4)
Esophagectomy 4240 32 (0.8) 36 (0.8) 86 (2.0) 2060 15 (0.7) 19 (0.9) 38 (1.8) 11
(1) Transhiatal
esophagectomy
244 3 (1.2) 2 (0.8) 5 (2.0) 33 1 (3.0) 0 1 (3.0)
(2) Transthoracic (rt.)
esophagectomy and
reconstruction
3638 26 (0.7) 30 (0.8) 68 (1.9) 1986 13 (0.7) 18 (0.9) 35 (1.8)
(3) Transthoracic (lt.)
esophagectomy and
reconstruction
110 1 (0.9) 0 1 (0.9) 3 0 0 0
(4) Cervical esophageal
resection and
reconstruction
133 0 0 2 (1.5) 11 0 0 0
(5) Others 38 1 (2.6) 1 (2.6) 3 (7.9) 7 0 0 0
(6) Esophagectomy
without reconstruction
77 1 (1.3) 2 (2.6) 6 (7.8) 20 1 (5.0) 1 (5.0) 2 (10.0)
(7) not specified 0 0 1 1 0 0 0 0
(Depth not specified) 5 0 0 0 0 0 0 0 0
Combined resection of
other organs
226 1 (0.4) 4 (1.8) 8 (3.5)
(1) Aorta 3 0 0 0
(2) Trachea, Bronchus 12 0 0 1 (8.3)
(3) Lung 56 0 2 (3.6) 2 (3.6)
(4) Others 155 1 (0.6) 2 (1.3) 5 (3.2)
Unknown 0 0 0 0
Salvage surgery 250 4 (1.6) 8 (3.2) 15 (6.0) 69 2 (2.9) 3 (4.3) 5 (7.2) 26
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Table 39 Mortality after combined resection of the neighbouring organs
Year Esophagectomy Combined resection
a b c (%) Aorta Tracheobronchus Lung Others
a b c (%) a b c (%) a b c (%) a b c (%)
1996 4194 120 2.86 7 3 42.86 24 0 0.00 50 2 4.00 78 4 5.13
1997 4441 127 2.86 1 0 0.00 34 5 14.71 56 1 1.79 94 3 3.19
1998 4878 136 2.79 4 0 0.00 29 0 0.00 74 1 1.35 128 2 1.56
1999 5015 116 2.31 5 0 0.00 23 2 8.70 68 0 0.00 122 1 0.82
2000 5350 81 1.51 2 0 0.00 23 2 8.70 69 0 0.00 96 1 1.04
2001 5521 110 1.99 1 0 0.00 26 1 3.85 83 3 3.61 99 2 2.02
2002 4904 66 1.35 3 1 33.33 20 2 10.00 63 0 0.00 63 1 1.59
2003 4639 45 0.97 0 0 0.00 24 2 8.33 58 0 0.00 88 1 1.14
2004 4739 64 1.35 2 0 0.00 17 0 0.00 59 5 8.47 119 2 1.68
2005 5163 52 1.01 1 0 0.00 11 1 9.09 67 1 1.49 73 1 1.37
2006 5236 63 1.20 0 0 0.00 17 0 0.00 62 2 3.23 122 3 2.46
2007 4990 60 1.20 0 0 0.00 25 1 4.00 44 1 2.27 138 2 1.45
2008 5124 63 1.23 0 0 0.00 17 1 5.88 48 1 2.08 185 0 0.00
2009 5260 63 1.20 0 0 0.00 19 2 10.53 58 2 3.45 211 3 1.42
2010 5180 45 0.87 2 0 0.00 33 0 0.00 58 0 0.00 245 5 2.04
2011 5430 38 0.70 4 0 0.00 26 0 0.00 41 0 0.00 179 5 2.79
2012 6055 47 0.78 2 0 0.00 23 1 4.35 69 0 0.00 240 1 0.42
2013 5824 41 0.70 2 0 0.00 44 0 0.00 77 1 1.30 156 3 1.92
2014 6244 47 0.75 2 0 0.00 24 0 0.00 77 3 3.90 227 3 1.32
2015 6151 39 0.63 3 0 0.00 15 0 0.00 67 3 4.48 266 4 1.50
2016 6158 40 0.65 3 0 0.00 12 0 0.00 56 0 0.00 155 1 0.65
Total 1,10,496 1463 1.32 44 4 9.09 486 20 4.12 1304 26 1.99 3084 48 1.56
aNumber of patients who underwent the operation
bNumber of patients who died within 30 days after operation
c% ratio of b/a, i.e., direct operative mortality
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